Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib, Trametinib, and Spartalizumab in BRAF V600E Metastatic Colorectal Cancer
NCT03668431Phase 2Unknown
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2018
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of spartalizumab in metastatic colorectal cancer (mCRC), sponsored by Massachusetts General Hospital. Status: unknown.
02
Drugs
spartalizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03668431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03668431.